Treatment-related adverse effects of any grade , which occurred in more than @ % of patients in the lenvatinib group , were hypertension ( in @ % of the patients ) , diarrhea ( in @ % ) , fatigue or asthenia ( in @ % ) , decreased appetite ( in @ % ) , decreased weight ( in @ % ) , and nausea ( in @ % ) .